rejuvant life tabs

Cancer blood test maker Grail files for Nasdaq IPO

Latest articles

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...
Rejuvant

Grail is on a quest for early cancer detection; the company is going public after raising nearly $2b in funding for its development of a simple blood test.

Despite reports of a potential IPO circulating over the past two years, Grail opted instead to acquire additional venture capital. However, it’s all change, as Grail announced today that it would list on the Nasdaq under the ticker “GRAL.”

Longevity.Technology: Grail was spun out from Illumina and backed by billionaires Bill Gates and Jeff Bezos, among many others. It has shown an unerring ability to raise money in support of its vast clinical programme which has 115,000 participants enrolled. Renaissance Capital estimated the deal could raise at least $500 million, but pricing terms have not yet been made public. There are plenty of tests that can monitor the progression of cancer, but Grail are focusing on early signature detection; this makes sense, as surely it’s better to catch cancer as early as possible – head it off at the pass, as it were, and minimise the harm and impact on lifespan.

This proactive, rather than reactive, approach to therapy – prevention, rather than cure – could prompt understanding of the early biomarkers of cancer, allowing tests to be developed that would catch precancerous cells. Being able to prevent cancer entirely would be an incredible boost to Longevity increasing both lifespan and healthspan

Earlier this year, Grail demonstrated that its liquid biopsy test could detect more than 50 different types of cancer across all growth stages. Also the test could even identify the specific organ where the tumour was located 93% of the time; it could do this from a single blood sample.

Shortly thereafter, the company closed its next funding round, raising $390 million in new investments from two Canadian national pension boards, as well as two undisclosed backers and returning investors.

Elevant

Grail says it has timetabled the commercial launch of its screening test, which is named Galleri, for 2021; it will initially be a lab-developed test, before the company seeks full clearance or approval from the FDA.

Blood sample in the lab. Source: aslysun / Shutterstock

Grail is also planning bring a separate blood test to market; this will be a diagnostic tool that will help oncologists focus their traditional cancer examinations for patients who are already exhibiting symptoms of an unidentified tumour.

Elevant

The blood test, which was teased at the American Association for Cancer Research annual research meeting in April, is slated to launch after Galleri in the second half of 2021.

As is usual, Galleri’s launch is tied to additional validation work; this is being completed through Grail’s 6,200-person Pathfinder study, which endured a hiatus after it was forced to suspend enrolment and sample processing earlier this year due to the COVID-19 pandemic. However, some study sites have resumed their work, so progress should be continuing shortly.

Image credit: Immersion Imagery / Shutterstock
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

FOXO exclusively licenses epigenetic clocks from UCLA

FOXO Technologies' exclusive licence of epigenetic clocks PhenoAge and GrimAge from UCLA could be an insurance game-changer. FOXO Technologies Inc has announced the licence of...

Can CRISPR be used to diagnose aging?

Irina Conboy talks CRISPR and how the gene-editing tech may have a significant role to play in diagnostics. In the first article from our interview...

Young blood to old – where do the answers to aging lie?

Irina Conboy talks parabiosis, plasma dilution, and why young blood may not hold the all answers. When it comes to scientific research in the world...

Muhdo partner with NUS in advanced longevity research

National University of Singapore and Muhdo Heath set to collaborate on an advanced global research project on longevity analysing epigenetic change. Muhdo Health announced today it...
Supps report ad middle